Two biotech companies, Octane Biotech and Currus Biologics, have successfully automated the production of a new cancer treatment called CUR-001. This means the therapy can now be made in a closed, consistent, and reliable way, which is important as it moves into human clinical trials. This milestone comes after the U.S. Food and Drug Administration (FDA) approved Currus’ application to start testing CUR-001 in patients, with the first doses expected to be given in early 2027.
CUR-001 is the first treatment from Currus’ BEAT platform. It combines a personalized CAR T-cell therapy with a special bispecific antibody. CAR T-cell therapy involves taking a patient’s own immune cells, modifying them in a lab to attack cancer, and then infusing them back into the patient. In this case, the therapy targets a protein called mesothelin, which is found in certain hard-to-treat solid tumors.
The BEAT platform is designed to overcome a major challenge in CAR T-cell therapy for solid tumors: the tumor’s ability to suppress the immune system and block the therapy from working effectively. By using a bispecific antibody, the treatment engages not only the CAR T-cells but also other immune cells to help activate the immune response more strongly.
To make CUR-001, the companies have moved the manufacturing process onto an automated system called the Cocoon, developed by Octane Biotech. This system reduces the need for manual handling and decreases the amount of viral vectors required, which are materials used to modify the cells. Both of these factors are major contributors to the high cost and time involved in making CAR T-cell therapies.
Sam Cobb, CEO of Currus Biologics, shared his thoughts on this progress: “Getting FDA approval to start clinical trials was a big step forward. Now, our focus is on ensuring we can produce CUR-001 reliably and consistently for each patient. The manufacturing process is critical to the success of this therapy.”
He added, “The move to the Cocoon system gives us a standardized, closed process that we can rely on as we begin clinical trials. It also provides a scalable model that can grow with the program.”
Louis Briggs, Vice President of Octane Biotech, explained why this automation is so important: “Currus has found a smart solution to one of the biggest challenges in cell therapy: making CAR T-cells work effectively against solid tumors.”
He continued, “Automating CUR-001 on the Cocoon means fewer manual steps, less variability between batches, and a process designed to expand as the clinical trials progress. We’re proud to support Currus as they prepare to treat their first patients.”
The manufacturing of CUR-001 for the phase 1 clinical trial will take place at Cell Therapies Pty Ltd in Melbourne, where the technology has been transferred and preparations are underway to start production.